Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                FDA-TRACK: Agency-wide Program Performance

FDA-TRACK: Agency-wide Program Performance

                        FDA-TRACK: What's New
          FDA-TRACK: User Fee Performance
          About FDA-TRACK
          FDA-TRACK: Site Map Home
          About FDA
          Transparency
          FDA-TRACK: Agency-wide Program Performance
          FDA-TRACK: Prescription Drug User Fee Act (PDUFA) PerformanceFDA-TRACK: Agency-wide Program Performance FDA-TRACK: Prescription Drug User Fee Act (PDUFA) Performance
  
  	
    Subscribe to Email Updates
    Share
    Post
    Linkedin

    Email
    PrintSubscribe to FDA-TRACK Updates


Menu

Prescription Drug Applications and Supplements

Procedural Notifications and Responses

Meeting
Management

• Current Performance
	• Historical Performance

• Current Performance
	• Historical Performance

• Current Performance
	• Historical Performance


Relevant Links:

• PDUFA VI Commitment Letter
	• PDUFA Amendments
	• PDUFA Reauthorization Act
	• PDUFA Performance Reports
	• FDA-TRACK: CDER Drugs and Biologics Dashboard


The Federal Food, Drug, and Cosmetic Act (the FD&C Act), as amended by the Prescription Drug User Fee Act of 2017 (PDUFA VI), authorizes FDA to assess and collect fees for prescription drug products from October 2017 through September 2022. FDA dedicates these fees toward expediting the drug development process and the process for the review of human drug applications, including postmarket drug safety activities.


The Prescription Drug User Fee Performance Dashboards (PDUFA Dashboards) provide a concise, interactive, and visual presentation of data presented in the legislatively mandated FY 2022 PDUFA Performance Report to Congress for the Prescription Drug User Fee Act (the Report). The PDUFA Dashboards are not intended to replace the Report and are to be used as a supplemental tool for viewing the data. The PDUFA Dashboards reflect performance on submissions received and actions taken as of September 30, 2022. The PDUFA Dashboards present final performance in meeting PDUFA goals for FY 2021 and preliminary performance for FY 2022. Final PDUFA performance data for FY 2022 will be presented in the FY 2023 PDUFA Report and referenced in updated versions of the PDUFA Dashboards.

Prescription Drug Applications and Supplements

The Prescription Drug Applications and Supplements Dashboard displays current performance relating to the review of:

Original Priority and Standard New Molecular Entities (NMEs) and Biologics License Applications (BLAs)
	Original Priority and Standard non-NME New Drug Applications (NDAs)
	Class 1 and Class 2 Resubmitted NDAs and BLAs
	Priority and Standard NDA and BLA Efficacy Supplements
	Class 1 and Class 2 Resubmitted NDA and BLA Efficacy Supplements
	NDA and BLA Manufacturing Supplements Requiring Prior Approval
	NDA and BLA Manufacturing Supplements Not Requiring Prior Approval

Procedural Notifications and Responses

The Procedural Notifications and Responses Dashboard displays current performance relating to the review of/responses to:

Proprietary Names Submitted During Investigational New Drug (IND) Phase and Submitted with NDA/BLA
	Major Dispute Resolutions
	Responses to Clinical Holds
	Special Protocol Assessments
	Human Factors Protocol Submissions

Meeting Management

The Meeting Management Dashboard displays current performance relating to the responses to/issuance of:

Meeting Requests
	Scheduling Meetings
	Written Responses
	Preliminary Responses
	Meeting Minutes

                                                                                  Content current as of:
      01/31/2023FDA-TRACK: Agency-wide Program Performance

          
                        FDA-TRACK: What's New
          FDA-TRACK: User Fee Performance
          About FDA-TRACK
          FDA-TRACK: Site Map
 Sign up to receive FDA-TRACK updates
                          Get regular FDA email updates delivered on this topic to your inbox.
    Enter your email address to subscribe:
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop